Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
8.45 | -0.33 (-3.76%) |
| Exchange : | NASDAQ (US Dollar) |
| Ric Code : | ORMP |
| Volume : | 463,326 |
| Date : | 04-16-2021 |
* Minimum 20 minute delay See terms
–
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]
Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA’s Approved Dual Concurrent Protocol
Patients screened in ORA-D-013-2 study which is recruiting 450 patients in 53 sites in the U.S., Europe and Israel NEW YORK, March 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company [...]
Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
The Oral Vaccine Successfully Produced Antibodies in a Preclinical Study After a Single Dose NEW YORK, March 19, 2021 /PRNewswire/ -- Good candidate for protection against COVID variants due to triple antigen targeting Implications for [...]
Oramed Reaches 25% Randomization in World’s First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol
ORA-D-013-1 study is recruiting 675 patients through 75 clinical sites throughout the U.S. NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of [...]
Oramed to Present at H.C. Wainwright Global Life Sciences Conference 2021
NEW YORK, March 4, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will [...]
Investors Tools